New Thrombectomy Product Launches Support PEN Stock Amid Macro Issues

Penumbra PEN is gaining traction in the U.S. and international markets on strong customer uptake of its Lightning Bolt and Flash lines. Yet, unfavorable currency movements and rising expenses are major dampeners for Penumbra. The stock carries a Zacks Rank #3 (Hold).Factors Driving PEN SharesPenumbra is demonstrating strong growth within the company’s Thrombectomy business, banking on the rapid increase in sales of the company’s vascular thrombectomy products in the United States as well as its CAVT line of products. In this region, the company is benefiting from sales of new products and further market penetration of existing products. In the fourth quarter of 2024, the company delivered 27.3% year-over-year growth in thrombectomy in the United States, driven by continued adoption and further market penetration of the current CAVT Portfolio, Lightning Flash 2.0, and Lightning Bolt 7. The U.S. VTE franchise delivered revenue growth of 41% year over year.Penumbra is still in the early stages of its journey to bring the company’s proprietary thrombectomy technologies to patients in the United States and around internationally. In terms of product launch, the Element Vascular Access System was launched in January 2025. This laser-cut hypotube sheath is designed for venous thromboembolism treatments and is compatible with the Lightning Flash 2.0 thrombectomy system.Penumbra also launched its Lightning Bolt 12 and Lightning Bolt 6x with TraX in 2025. These additions to Penumbra's Computer-Assisted Vacuum Thrombectomy (CAVT) platform aim to enhance arterial and venous thrombus management. In terms of pipeline, the company plans to strongly focus on Flash and Bolt innovations.Penumbra derives a significant portion of its revenue internationally (24.5% in 2025). The company expects to materially increase both revenues and profitability in the company’s international business in the next few years. During this period, it expects to bring its franchise products like RED catheters and CAT RX together with all its most advanced products, Lightning Flash, Lightning Bolt 7 and Thunderbolt, to Penumbra global teams.Penumbra, Inc. Price Penumbra, Inc. price | Penumbra, Inc. QuoteOver the past three months, shares of PEN have gained 16.7% against the industry’s 5.6% dip. The company’s consistent efforts to expand its high-growth thrombectomy business, as well as its array of new product launches, are expected to help the stock continue with its uptrend in the coming days.Concerns Remain for PenumbraA significant portion of Penumbra’s sales and costs are exposed to changes in foreign exchange rates. In 2024, approximately 29% of the company's consolidated revenues came from the non-U.S. markets. The company’s operations use multiple foreign currencies, including the euro and Japanese yen. Changes in those currencies relative to the U.S. dollar will impact its sales, cost of sales and expenses and consequently, net income.Like other industry players, Penumbra’s business is currently impacted by worldwide geopolitical complications leading to widespread impact on global supply chains and labor markets. These have resulted in cost escalation and raw material supply constraints, as well as an increase in employee turnover rates in certain jurisdictions. All these factors are putting significant pressure on Penumbra’s profitability. In the fourth quarter of 2024, the company incurred a 7.3% rise in the cost of revenues. Selling, general and administrative expenses rose 13.8% year over year.Key PicksSome better-ranked stocks in the broader medical space include Hims & Hers Health HIMS, Boston Scientific BSX and Cardinal Health CAH. Each of these carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.Estimates for Hims & Hers Health’s 2025 earnings per share have jumped 21.2% to 63 cents in the past 30 days. Shares of the company have surged 113% in the past year against the industry’s 10.8% fall. Its earnings yield of 1.8% also outpaces the industry’s -4.6% yield. HIMS’ earnings surpassed estimates in two of the trailing four quarters, matched in one and missed on another occasion, the average surprise being 40.4%.Boston Scientific shares have rallied 49.6% in the past year. Estimates for the company’s 2025 earnings per share have remained constant at $2.85 in the past 30 days. BSX’s earnings beat estimates in each of the trailing four quarters, the average surprise being 8.3%. In the last reported quarter, it posted an earnings surprise of 7.7%.Estimates for Cardinal Health’s fiscal 2025 earnings per share have increased 1 cent to $7.94 in the past 30 days. Shares of the company have jumped 18.8% in the past year against the industry’s 3.5% fall. CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 9.6%. In the last reported quarter, it delivered an earnings surprise of 10.3%.7 Best Stocks for the Next 30 DaysJust released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.3% per year. So be sure to give these hand picked 7 your immediate attention. See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX): Free Stock Analysis Report Cardinal Health, Inc. (CAH): Free Stock Analysis Report Penumbra, Inc. (PEN): Free Stock Analysis Report Hims & Hers Health, Inc. (HIMS): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks